Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company founded in 2012 with a focus on developing innovative cancer treatments through its proprietary INTASYL™ RNAi technology. This technology aims to enhance the effectiveness of immune cells in killing tumor cells by precisely targeting specific proteins that diminish the body’s ability to combat cancer. Co-founded by Nobel Laureate Craig Mello, who received the Nobel prize in 2006 for his discovery of RNAi, the company holds a pioneering position in immuno-oncology therapeutics. The technology's self-delivering nature eliminates the need for specialized formulations or drug delivery systems, positioning Phio at the forefront of the industry. The company's commitment to redefining cancer treatment aligns with its mission to create new pathways for a cancer-free future. Its post-IPO equity investment on 12th July 2024 reflects the confidence of investors in the potential impact of Phio's technology. As the biotechnology and healthcare industries continue to evolve, Phio Pharmaceuticals Corp. stands out as a promising player with a compelling vision for reshaping cancer therapeutics. More information about the company can be found on its website, www.phiopharma.com. #INTASYL #siRNA #RNAi #Phio #immunooncology